Current Share price could increase due to investor excitment:
- PAR received Therapeutic Goods Administration (TGA) provisional approval on 25th October 2019 = Possible revenue generation next year
- PAR expects to meet FDA approval requirements within 2019
- PAR is expected to treat 10 ex-US NFL patients within Q1 of 2020 with Zilosul drug = efficacy evidence
- These exciting and revenue provoking events could see current price rise higher
Current Share price could increase due to investor excitment: -...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.010(3.51%) |
Mkt cap ! $96.19M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 27.0¢ | $45.01K | 159.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 17942 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 9634 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
27.5¢ |
Change
-0.010 ( 3.51 %) |
||||
| Open | High | Low | Volume | ||
| 29.0¢ | 29.0¢ | 27.0¢ | 41613 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| PAR (ASX) Chart |